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Abstract
Autoantibodies produced against self-antigens, or ‘autoantigens’, result from a loss of self-
tolerance triggered by genetic and/or environmental factors which induce the immune 
system to attack the host’s own cells, resulting in a condition referred to as autoimmunity. 
In classic autoimmune diseases, it is well established that the pathology relates directly 
to the autoantibodies. However, it is increasingly recognised that autoantibodies are also 
found in many other disease areas, including cancers, cardiovascular and neurodegenera-
tive diseases, as well infectious diseases such as malaria, albeit in such diseases it is unclear 
whether the autoantibodies play a direct role in the pathology or whether they are merely 
symptomatic of disease. Irrespective of whether they are causative or symptomatic of spe-
cific diseases though, there is increasing interest globally in exploring the clinical potential 
of circulating autoantibodies as diagnostic biomarkers. This chapter provides an overview 
of the diagnostic utility of autoantibody biomarkers in a range of disease areas and dis-
cusses their potential utility in disease staging, treatment monitoring and in prediction 
of immune-related adverse events. It also provides an overview of traditional and con-
temporary technological approaches to autoantibody biomarker discovery and validation, 
focusing on protein microarrays that are ideally suited to this important area of research.
Keywords: autoantibody biomarkers, protein microarrays, pre-symptomatic diagnosis, 
immune-related adverse events
1. Introduction
Autoantibodies are natural antibodies produced against self-antigens, or ‘autoantigens’, 
and can induce the immune system to attack host tissues, leading to a condition generically 
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referred to as autoimmunity. Classic autoimmune syndromes include systemic lupus erythe-
matosus, rheumatoid arthritis, rheumatic heart disease, Graves’ disease, autoimmune hepa-
titis, multiple sclerosis, diabetes, and Sjogren’s syndrome. In such autoimmune diseases, it 
is well established that the pathology relates directly to the autoantibodies. However, it is 
increasingly recognised that autoantibodies are also found in many other diseases, includ-
ing cancers, cardiovascular diseases, neurodegenerative diseases, as well infectious diseases 
such as malaria, albeit in such diseases it is not yet clear whether the autoantibodies play a 
direct role in the pathology or whether they are merely symptomatic of disease. Irrespective 
of whether the autoantibodies are causative or symptomatic of specific diseases though, there 
is increasing interest globally in exploring the clinical potential of circulating autoantibodies 
as diagnostic biomarkers and considerable research effort is now being directed to the discov-
ery, quantitation and validation of novel autoantibody-based diagnostic biomarkers in many 
different disease areas.
Numerous techniques have been utilised over the last few decades to detect the pres-
ence of autoantibodies in patient samples, not least since autoantibodies are increasingly 
thought to represent excellent potential biomarkers for early disease detection. Techniques 
that have historically been employed for biomarker identification include western blot-
ting, immunohistochemistry and enzyme-linked immunosorbent assays (ELISA), but these 
are being superseded now by newer technologies that offer higher multiplicity as well as 
greater sensitivity and specificity. Amongst these newer technologies, protein microarrays 
are becoming established now as a powerful means to detect protein expression levels and 
to investigate protein-ligand interactions, as well as to probe protein function [1], since 
they enable efficient and sensitive, high throughput protein analysis, with large numbers 
of technically-replicated measurements being made in parallel using miniaturised assay 
formats and minimal sample volumes. These properties of protein microarrays make 
them ideally suited to component-resolve and quantify autoantibody profiles in biological 
samples.
2. Autoantibodies: a brief overview
2.1. Autoantibody classes
Antibodies are secreted heterodimeric proteins comprising light and heavy chains which 
are produced in mammals through recombination of V(D)J segments in developing 
B-lymphocytes. At any one time, there are thought to be of the order of 107–108 different 
antibody sequences present in human serum. In response to the presence of foreign anti-
gens or pathogens, somatic hypermutation processes drive the affinity maturation of specific 
antibody sequences, resulting in the production of high affinity, antigen-specific antibodies. 
Affinity-matured antibodies, or immunoglobulins (Igs), are produced by plasma cells and 
secreted into the blood stream where they scavenge their cognate antigen for destruction. 
Antibodies thus play a crucial adaptive role in mammalian defence mechanisms against 
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harmful components that can cause disease. There are five classes of antibodies: IgG, IgM, 
IgE, IgD and IgA, which differ in their structures and immune functions. IgG is the major anti-
body class found in blood, has the longest serum half-life of all immunoglobulin isotypes [2] 
and contributes directly to a neutralising immune response to extracellular pathogens and 
toxins. IgA is also involved in direct neutralisation of toxins, virus and bacteria; however, 
it concentrates particularly in mucosal surfaces. IgM, a pentameric immunoglobulin, is the 
largest of the antibody classes and is associated with a primary immune response; IgMs are 
therefore frequently used to diagnose acute exposure to an immunogen or pathogen [2]. 
IgD and IgE are found in trace amounts in the blood with short half-lives. IgD remains 
membrane-bound and is involved in regulation of cell activation while IgE is associated with 
hypersensitivity and allergic reactions [2]. Classical autoantibodies are typically IgMs and 
include: anti-nuclear antibodies (ANA), which bind to the nuclear membrane, nucleoplasm, 
nucleoli and nuclear organelles of cells [3]; rheumatoid factor (RF), which binds with rela-
tively low affinity to the Fc region of IgGs and which is found in the serum of rheumatoid 
arthritis (RA) patients [4]; Anti-double-stranded DNA (dsDNA) antibodies, anti-Sm anti-
bodies, antiphospholipid antibodies, anti-Ro, anti-ribonucleoprotein and anti-La Antibodies 
which are all frequently found in systemic lupus erythematosus (SLE) patients [4]; and Anti-
Sjogren’s syndrome A (SSA) and -B (SSB) antibodies, which are found in many patients with 
Sjogren’s syndrome [4].
2.2. Causes of autoantibody production
In a normal immune response to a foreign antigen, professional antigen presenting cells - 
including dendritic cells, B-cells and macrophages – engulf and proteolyse the antigen and 
then present antigen-derived peptides on their cell surface in the form of major histocom-
patibility complexes; recognition of complexed peptides by a specific receptor on a T-cell 
then triggers the release of cytokines and chemokines, resulting in activation of that T-cell. 
Interaction between antigen-specific T- and B-cells subsequently leads to antigen-specific 
B-cell proliferation [1, 2]. A portion of those B-cells serve as memory cells, whilst the remain-
der act as effector cells that differentiate into antibody-producing plasma cells responsible for 
the production and release of antigen-specific antibodies [5].
Peripheral tolerance mechanisms usually ensure that self-reactive T- and B-cells (i.e. dis-
playing T- or B-cell receptors for self-antigens) are suppressed. However, in certain circum-
stances, peripheral tolerance can be broken, resulting in proliferation of autoantigen-specific 
T- and B-cells. Simplistically, peripheral tolerance can be broken for a number of reasons, 
for example if the self-antigen is significantly over-expressed in a tissue or if neoantigens 
are somehow presented to the host immune system. Such neoantigens can include mutated 
peptide epitopes, aberrantly spliced or aberrantly post-translationally-modified epitopes, or 
new discontinuous epitopes resulting from misfolding of the antigen. Tolerance defects can 
also stem from the downregulation of regulatory T-cells (Tregs) [6], whilst chronic inflam-
matory responses are thought to facilitate the release and exposure of intracellular antigens 
to the immune system, resulting in autoantibody production in cancer patients [7], as well as 
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increased vasculature permeability, allowing immune cell accumulation at the tumour site 
[8]. One consequence of loss of peripheral tolerance can be the production of self-antigen-
specific autoantibodies.
As mentioned above, autoantigens may result from aberrant post-translationally modifica-
tions, including proteolysis, hydrolysis, phosphorylation and oxidation [9]. One such exam-
ple occurs in RA, where patients produce autoantibodies against citrulline-modified proteins, 
themselves produced by the enzymatic action of peptidylarginine deiminases (PADs) - cal-
cium-dependent enzymes that catalyse the post-translational hydrolysis of peptidylargi-
nine to peptidylcitrulline. During inflammation, oxidative stress or apoptosis, PAD converts 
specific arginine residues on selected proteins into citrulline (a process often referred to as 
‘citrullination’), thereby producing neoepitopes that are recognised as non-self, dramatically 
altering immunogenicity and autoantibody production in RA patients [10].
Autoantibodies are also produced in response to the uncontrolled released of autoantigens 
during cell death processes. Maintenance of tissue homeostasis ordinarily takes place via 
clearance of apoptotic and altered cells through phagocytosis- or complement-dependent 
mechanisms, inhibition of inflammation, removal of misfolded proteins, and regulation of 
autoantibody-producing B cells [11]. However, when clearance mechanisms becomes com-
promised, dead cells accumulate and progress to secondary necrosis, releasing autoanti-
gens as well as pro-inflammatory markers and thereby disrupting immune homeostasis [12] 
(Figure 1).
Autoantibody production thus has a multifactorial aetiology in which environmental 
and inherited factors interplay in determining the autoantibody profiles of an individual. 
Environmental factors associated with autoantibody production include drugs, toxins, 
chemicals from personal care products, and infections. Exposure to such agents can result 
in modification or mutation of chromosomal DNA sequences, potentially giving rise to 
altered gene- and protein expression (which can drive altered post-translational modifica-
tions), as well as to the expression of aberrantly-spliced or mutated form of proteins, all of 
which can result in the generation of neoantigens in the exposed tissue and hence to the 
production of specific autoantibodies. Furthermore, genetic predisposition or family his-
tory of autoimmune disorders also contributes to one-third of the risk of having increased 
autoantibody levels and various genome-wide association studies have shown that the pro-
duction of autoantibodies in SLE [13], RA [14] and Multiple Sclerosis [15] is controlled by 
multiple loci.
Although the self-reactivity of autoantibodies can be harmful to host tissues, recent studies 
suggest that low-grade self-reactivity also occurs in healthy individuals, implying that cer-
tain autoantibodies may play a role in maintaining immune homeostasis [16] and in protect-
ing against pathogenic processes, by activating innate and acquired immunity to maintain or 
restore health status [16]. Natural autoantibodies are predominantly of the IgM class, which 
makes sense since IgM is the first antibody to appear when the immune system is triggered 
in response to external antigenic exposure. By contrast, circulating naive IgMs arise without 
known immune exposure or vaccination [11] but have also been reported to recognise certain 
autoantigens in healthy adults as well as in newborn babies [17, 18].
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2.3. Gender bias in autoimmune diseases
The term ‘autoimmune disease’ refers to a group of over 80 distinct disorders, the symptoms 
and severity of which vary between individuals [19].
There are marked differences in diseases that predominantly affect males or females, as 
shown in Figure 2. Generally, females are more susceptible to autoimmune diseases whereas 
males show increased susceptibility to non-reproductive cancers. As females tend to have 
more responsive and robust immune system compared to their male counterparts, it is there-
fore not surprising that females respond more aggressively to autoantigens and are more 
susceptible to autoimmune diseases [20]. Other factors that contribute to the sex bias of auto-
immune diseases include X-chromosomal abnormalities, X-chromosomal inactivation, and 
fetal micro-chimerism [20].
2.4. Functional role of autoantibodies in disease
The outcome of aberrant activation of the immune system and inflammatory process is depen-
dent on multiple factors, including the type of affected tissue or organ and the degree of tissue 
injury sustained [21]. For example, in type 1 diabetes mellitus, the immune system reacts to 
insulin-producing cells in the pancreas. In other examples, tissues of the small intestines are 
Figure 1. Key factors that increase antigenic pressure and cause the production of autoantibody in several diseases.
Autoantibody-Based Diagnostic Biomarkers: Technological Approaches to Discovery and Validation
http://dx.doi.org/10.5772/intechopen.75200
163
affected in inflammatory bowel disease, while myelin - a fatty substance that protects nerve 
fibres in the brain and spinal cord - is destroyed in Multiple Sclerosis. In RA, connective tis-
sues are affected and in SLE, auto-reactivity usually occurs in skin, heart and lung tissues. 
Sjogren’s syndrome occurs when autoantibodies target secretory glands that produce tears 
and saliva, causing extreme dryness and other complications [22].
In other diseases, however, the functional role of autoantibodies is less clear. For example, in 
neurodegenerative diseases such as Parkinson’s and Alzheimer’s Diseases, increased cellular 
toxicity is caused by the accumulation and aggregation of misfolded proteins, which might 
also result in the generation of protective autoantibodies in some patients. For example, in 
Parkinson’s Disease (PD), the protein alpha-synuclein misfolds and aggregates to form Lewy 
bodies; these bodies form in the brain tissues of PD patients and infiltrate the neurons, dis-
rupting signalling process in the brain. A recent study reported that a defined set of epitopes 
derived from alpha-synuclein drive cytotoxic T-cell responses in people with PD [23], whilst 
another recent study reported a decline in anti-alpha-synuclein autoantibodies in PD patients 
compared to controls, suggesting that in some patients anti-alpha-synuclein autoantibodies 
might play a protective role [24].
Similarly, in Alzheimer’s Disease (AD), the microtubule-associated protein Tau accumu-
lates and aggregates in neurons causing neuronal degeneration. Tau also accumulates and 
Figure 2. Gender-dependent susceptibility to autoimmune diseases, infectious diseases, inflammatory diseases and 
cancers.
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aggregates in Progressive Supranuclear Palsy (PSP), a rare disease often misdiagnosed as 
Parkinson’s disease. In AD, Tau causes misfolding of beta-amyloid, leading to amyloid-β (Aβ) 
plaque formation and downstream pathology, but in PSP, Tau itself mis-folds and agglomer-
ates. These protein agglomerations subsequently leave the cell, spread throughout the brain 
and disrupt the communication between neurons [25]. Interestingly, a recent study identi-
fied an anti-Aβ plaque autoantibody in certain aged but cognitively firm individuals that 
was absent in AD patients; this autoantibody was cloned and has been shown to selectively 
target aggregated Aβ in a mouse model of AD, where it bound parenchymal Aβ and reduced 
soluble and insoluble Aβ in a dose-dependent manner; in Phase 2 clinical trials, this autoan-
tibody, Aducanumab, reduced brain Aβ in patients with mild AD, again in a dose-dependent 
manner [26], strongly suggesting that anti- Aβ autoantibodies play a protective role in healthy 
individuals.
In cancers, chronic inflammation is a well-recognised hallmark and it is known that both 
cancer and autoimmune diseases can occur in the same individual, albeit in cancer, the 
immune response is often suppressed and unable to eliminate altered self-cells, while in auto-
immune diseases it is hyper-activated against specific autoantigens. The act of manipulat-
ing the immune system in different ways, however, suggests a possible link between these 
two conditions [21] and it seems likely that inflammatory processes drives both autoim-
munity and malignancy. However, it remains unclear whether it is the underlying autoim-
munity that leads to malignancy (“inflammation-induced cancer”) or whether the immune 
responses directed against tumour antigens lead to autoimmune diseases (“tumour-induced 
autoimmunity”).
3. Diagnostic utility of autoantibody biomarkers
3.1. Early detection of disease
Autoantibody production is a key indicator of many diseases and has emerged as an impor-
tant tool in predicting onset of a number of diseases. Autoantibodies are in principle detect-
able many years before manifestation of disease or symptoms and have been observed in an 
ever-widening range of disease areas, which makes novel autoantibodies attractive plausible 
biomarkers for early diagnosis of a broader spectrum of diseases now. Known autoantibody 
biomarkers have been reported to predate symptoms in Sjogren’s syndrome, rheumatoid 
arthritis, Alzheimer’s disease and cancers, as discussed below:
Sjogren’s syndrome is an autoimmune disease that affects parts of the body which produce 
secretions such as tears and saliva. The symptoms overlap with other autoimmune conditions 
and can range from mild to severe, causing nausea, fatigue, joint pain as well as excessive 
dryness of the eyes and mouth. Autoantibodies attack cells in mucous membranes and mois-
ture-secreting glands of the eyes and mouth, causing dryness, irritation and pain. A study 
published in 2015 concluded that autoantibodies are present up to 18–20 years before the 
diagnosis of primary Sjogren’s syndrome [27]. A total of five autoantibodies were analysed, 
namely antinuclear antibodies, rheumatoid factor and autoantibodies against Ro 60/SSA, Ro 
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52/SSA, and La/SSB, with 81% of the patients who became seropositive after diagnosis hav-
ing autoantibodies in pre-diagnostic serum samples. More importantly, these autoantibodies 
were present in the earliest available serum sample of 95% of the patients who expressed 
autoantibodies before diagnosis and before the onset of first symptoms [27].
RA is a chronic autoimmune disease characterised by inflammation of synovial joints, lead-
ing to joint erosion and deterioration. Rheumatoid factor and anti-cyclic citrullinated peptide 
(anti-CCP) are detected in the blood of 80% and 60–70% of RA-affected individuals, respec-
tively. Anti-CCP autoantibodies were detected in some patient sera samples 12–14 years prior 
to the development of RA and 34–40% of the RA patients were anti-CCP positive prior to 
disease onset [28].
The presence of autoantibodies has also been implicated in AD. Aβ-autoantibodies were 
reported to show promise as an effective blood biomarker for AD and a positive association 
between Aβ-autoantibody titres and cognitive status have been reported [29]. Glial autoan-
tibody markers to glutamate were detected in the plasma of AD patients and, interestingly, 
the level of that autoantibody in patients with moderate and severe dementia was 2-fold 
higher than that in patients with mild dementia [30]. In addition, autoantibodies to ATP syn-
thase were reported to be found frequently in the sera of AD patients but not in age-matched 
healthy subjects or in patients with Parkinson’s disease or atherosclerosis, suggesting anti-
ATP synthase autoantibodies could be a specific biomarker for AD [29].
In addition to autoimmune diseases, multiple studies have described autoantibody produc-
tion prior to cancer diagnosis, including in lung cancer [31], prostate cancer [32] and ovarian 
cancer [33]. Autoantibody production in cancer is thought to be a product of immunosurveil-
lance - a process in which the body’s own systems recognise and eliminate abnormal cells 
during early tumorigenesis [34] - suggesting that detection of disease-associated autoantibod-
ies may be feasible in the asymptomatic stages of cancer and may predate the clinical signs of 
tumour progression by months or years, thus enabling their use in early diagnosis [35].
By way of example, in healthy mammalian cells, cAMP-dependent protein kinase A (PKA) 
is an intracellular enzyme, while in most cancers it is secreted into the circulatory system 
as ECPKA. The level of ECPKA was found to be elevated in various stages of a wide range 
of cancers including bladder, breast, cervical, colon, esophageal, gastric, liver, lung, ovar-
ian, prostate, pancreatic, renal, small bowel, rectal, adenocystic carcinomas, melanoma, sar-
coma, thymoma, liposarcoma, and leiomyosarcoma compared with healthy controls [35]. 
Extracellular protein kinase A (ECPKA) autoantibody is thus a potential serologic autoanti-
body for early-stage cancers diagnosis since it presents at high levels before surgical removal 
of solid tumours and diminishes after tumour removal [36]. An ELISA-based test for anti-
ECPKA IgG was developed and the sensitivity and specificity of this biomarker for detect-
ing 20 different cancers were reported to be 90 and 87% respectively, with the anti-ECPKA 
autoantibody being detected in 90% of the patient samples but in only 13% of the control 
samples [35].
Autoantibody-based screening for a variety of other cancers has also been carried out in lab-
oratory environments. For example, Xie et al. developed a test platform by combining the 
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detection of six autoantibodies directed against prostate cancer with PSA levels, increasing 
the accuracy of detection from 65% using PSA alone to 81% with both methods [37]. A similar 
outcome was achieved in breast cancer diagnosis using a panel of six autoantigens to detect 
ductal carcinoma in situ and lung cancer with specificity of 85 and 92%, respectively [38]. It is 
thus evident that having an increased level of specific circulating autoantibodies may reflect 
the overall state of the immune response of an individual, whilst the presence of such auto-
antibodies in otherwise healthy individuals might be an indicator of future autoimmune or 
other disorders.
3.2. Disease staging and treatment monitoring
An accurate pathology diagnosis is of central importance in precision medicine, since it 
should guide choice of the most effective treatment and management regimens. Reliable 
biomarkers for monitoring and prediction of disease course, stage and progression will be 
therefore invaluable, particularly in therapeutic decision-making to treat disease at an early 
stage. Current research has not only established the presence of autoantibodies in several 
diseases but has also shown that they have the potential to be used as biomarkers capable 
of diagnosis and staging various degrees of pathology. One such example is Type 1 insulin-
dependent diabetes - a chronic autoimmune disease that impairs the insulin-producing beta 
cells in the pancreas, preventing the body from producing enough insulin to regulate blood 
glucose levels. This disease can be characterised into well-defined stages, and the rate of 
progression to symptomatic disease can be predicted with appreciable accuracy [39]. Stage 1 
is defined by the presence of two or more islet autoantibodies and progressing at a variable 
rate to a second stage of glucose intolerance or dysglycaemia, before becoming clinically 
symptomatic (stage 3).
In another example, Cai et al. reported that anti-p53 antibodies develop several years before 
the clinical diagnosis of certain cancers and suggested that monitoring the change of serum 
p53 antibodies before and after treatment of patients diagnosed with oesophageal carcinoma 
with radiotherapy would be useful for evaluating the prognosis and response to the treat-
ment. This study showed that the positive rate of p53-antibodies in patients with oesophageal 
carcinoma was related to histological grade, stage of the disease and lymph node metastasis 
but not to age, gender, or site of tumour formation. The study also reported a significant dif-
ference in the level of serum p53 antibodies before and after radiotherapy treatment, with the 
positive rate of p53 antibodies in patients who responded to radiotherapy being much lower 
than the patients who did not respond to radiotherapy [40]. A separate study by Shimada 
et al. showed that seropositive oesophageal squamous cell carcinoma patients, whose serum 
anti-p53 titre did not decrease after surgery, exhibited worse prognosis than patients who 
showed seroconversion. Thus, a correlative study between the level of tumour autoantibodies 
and the overall survival outcome of cancer patients (reflected in the change in tumour sta-
tus or tumour burden related to the therapy) could be extremely informative for evaluating 
therapeutic interventions [41]. Stage-specific autoantibody biomarkers screening is thus in 
principle useful in predicting onset of disease, thereby providing an opportunity to intervene 
and delay or prevent the onset of clinical symptoms.
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3.3. Immune-related adverse events
Immunotherapies have been changing the outlook for many cancer patients in recent 
years and immune checkpoint inhibitors represent one of several strategies now targeting 
the immune system for therapeutic benefits. The immune checkpoint proteins cytotoxic 
T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1) play 
essential roles in central immune tolerance and are prominent targets for cancer vaccines 
now since inhibition of CTLA-4 and PD-1 can (re)activate the immune system to target can-
cer cells. Alone or in combination, clinical trials of anti-CTLA-4 and anti-PD-1 antibodies, 
such as Ipilimumab, Nivolumab and Pembrolizumab, have shown promising results for 
the treatment of melanoma, non-small cell lung-, kidney-, prostate- and head and neck can-
cers, as well as renal cell carcinomas, with reported therapeutic response rates approaching 
70% in some cases, albeit positive immunotherapy outcomes remain cancer- and patient-
specific [42].
Ipilimumab was the first anti-CTLA-4 antibody to prolong survival in patients with 
advanced melanoma [43, 44], with long term analysis indicating a 3-year survival of 22% 
across all patients with sufficient follow-up [45]. Similarly, PD-1 blockade with Nivolumab 
or Pembrolizumab has improved survival for metastatic melanoma, non-small cell lung 
cancer (NSCLC) and renal cell carcinoma (RCC) patients [46–50]. In one trial, advanced 
melanoma patients treated with pembrolizumab showed a response rate of 34% and a 
survival rate of 74% [51]. Nivolumab has been reported to result in increased response 
rates, survival and progression-free survival when compared to intravenous docetaxel in 
NSCLC [52], whilst stage III/IV melanoma patients achieved a partial tumour response, 
with a median progression free survival of 172 days, with only 18% experiencing grade 2 
or 4 adverse events [53].
Combination check-point inhibitor treatments, targeting both CTLA-4 and PD-1, have also 
shown strong promise, with clinical trial data in untreated melanoma patients reporting 
objective response rates up to 72% (amongst patients with PD-L1-positive tumours) and with 
median progression-free survival of 11.5 months for ipilimumab plus nivolumab, compared 
to 2.9 months with ipilimumab alone and 6.9 months with nivolumab alone [54]. However, 
high grade immune-related adverse events (irAEs) occurred in 55% of those in the combina-
tion treatment group [54] and similarly high rates of irAEs have been reported elsewhere for 
anti-CTLA-4 and anti-PD-1 treatments [55].
Indeed, clinical findings on monoclonal antibody-induced adverse effects in general show 
that this is a wider phenomenon across different disease areas [56], which potentially com-
promises the effectiveness of such immunotherapies. Efforts are being channelled therefore 
towards predicting and monitoring undesirable immunotoxic effects and a panel of poten-
tial antibodies associated with irAE has been proposed (Table 1). Further exploratory stud-
ies involving autoantibody-based immunotoxicity profiling in immunotherapy patients are 
underway to better characterise the role and diagnostic potential of these circulating autoan-
tibodies in irAE.
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4. Classical technological approaches to autoantibody-based 
biomarker discovery and validation
4.1. Western blots
Since its introduction in 1979, immunoblotting, or ‘western blotting’, has become a ubiquitous 
protein analysis technique in which proteins are separated by electrophoresis according to 
Immune-related organ 
involved
Antibodies
Gastro-intestinal None
Liver Antinuclear antibodies (ANAs)
Anti-smooth muscle, anti-liver kidney microsomal antibody type 1, anti-liver cytosol 
type 1
Lung Antinuclear antibodies (ANAs)
Rheumatoid factor
Anti-centromere
Extractable nuclear antigens (ENA): anti-Sm, anti-RNP: anti-Ro (SSA)
Anti-La (SSB): anti-Scl70, anti-Jo
Endocrine Anti-GAD, anti-insulin, anti-carbonic anhydrase
Anti-21 hydroxylase
Anti-pituitary
Skin None
Polyarthritis Antinuclear antibodies (ANAs)
Anti-ENA: anti-SSA, SSB, Sm
Anti-CCP, complement fractions C3 C4 CH50
Renal Antinuclear antibodies (ANAs)
Complement fractions C3 CA CH50
Anti-neutrophil cytoplasmic (ANCA)
Haematologic syndromes Antinuclear antibodies (ANAs)
Coombs’ erythrocyte test
CCP, cyclic citrullinated peptide; GAD, glutamate decarboxylase; RNP, ribonucleoprotein; Sm, small nuclear 
ribonucleoprotein; SSA, Sjogren’s syndrome-related antigen A; Scl, Sclerosis systemic; SSB, Sjogren’s syndrome-related 
antigen B.
Table 1. List of proposed potential seromic autoantibodies that can be used for identifying irAEs [55].
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their molecular weight, then transferred onto a membrane before a primary antibody specific 
to the protein of interest is used to detect the presence and relative abundance of the target 
protein. Conventional western blotting allows detection of specific proteins to the level of 
single isotypes. However, it is associated with poor reproducibility, limited mass resolution, 
lack of accurate quantitation, low throughput and lengthy time to result, whilst non-specific 
cross-reactivity of mono- and poly-clonal primary and secondary antibodies on the blots is an 
everyday observation.
Certain modifications have been proposed to improve quantitation of western blots; for exam-
ple, Zellner et al. reported a novel and improved quantitative Western blotting method using 
fluorescently labelled secondary antibodies, which extends the dynamic range of quantifica-
tion and improves correlation with the protein amount [57]. Modifications based on simul-
taneous electrophoretic transfer of proteins from multiple strips of polyacrylamide gels to a 
single membrane sheet have also been reported to increase the data output per single blotting 
cycle by up to 10-fold [58], whilst resulting in reduced immunoblotting-derived signal errors 
and improving the overall data accuracy [58]. However, in the context of biomarker discov-
ery, western blotting is typically only used as a validation method rather than as a primary 
method of identifying biomarkers.
4.2. Enzyme-linked immunosorbent assay (ELISA)
ELISA, unlike western blotting, is adaptable to higher throughput of samples as it is typically 
performed in 96-well microtitre plates whereby plate handling and detection systems can be 
automated. ELISA can be used to determine the exact amount of a specific protein in a sample, 
making it more readily quantitative as a technique compared to western blotting. The signals 
are usually produced by chromogenic reaction that generate a coloured product, which is 
quantified by spectrophotometry. There are four types of ELISA – sandwich, direct, indirect 
and competitive – which essentially differ in whether the antigen or a capture antibody is 
immobilised onto the surface (Figure 3).
In the context of autoantibody detection, the direct and indirect ELISA formats are most com-
monly used, but are better suited to the analysis of a larger number of samples against a 
small number of antigens in screening, verification and validation applications rather than as 
a primary discovery platform [59]. Furthermore, standard ELISA often has relatively low sen-
sitivity and detection usually depends on enzymatic amplification of signal at the end of the 
assay. In addition, ELISA can also give false positives due to cross-reactivity of the detecting 
antibodies with other proteins in the sample. As sensitivity and specificity are prerequisites 
of any biomarker discovery platform, traditional ELISA may not be the ideal choice when it 
comes to identifying biologically relevant and meaningful disease biomarkers.
4.3. Mass spectrometry
The use of mass spectrometry for serum biomarker discovery is in theory straightforward 
since results are obtained in the form of identified and quantified proteins that are then com-
pared between pathological and control groups [60]. Recent advances in mass spectrometry 
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instrumentation have significantly improved the depth, breadth and reproducibility of pro-
tein identifications in many biological samples, which in turn has aided the identification of 
meaningful signatures that have diagnostic potential. However, whilst mass spectrometry is 
in general a powerful approach for unbiased biomarker identification, there are some limita-
tions, particularly in serum biomarker discovery, due to the complex nature of serum and its 
wide dynamic range of protein concentrations (spanning 12-orders of magnitude), as well 
as to the intrinsic mass spectrometry sensitivity (>μg/mL) in detecting analytes which usu-
ally range between 50 pg/mL and 10 ng/mL in serum [60]. Furthermore, mass spectrometry-
based proteomics remains heavily constrained today in its ability to differentiate and assign 
function to individual antibody sequences within a large collection of immunoglobulins: this 
is partly because the affinity-matured antibody sequences are not germ-line encoded (and 
therefore do not appear in the proteome databases that underpin tandem mass spectrometry-
based protein identifications) and is partly because both light and heavy chains are required 
for antigen specificity in an immunoglobulin, yet that pairing between light and heavy chain 
sequences (as well as the connectivity between the complementary determining regions with 
each light and heavy chain) is lost during proteolytic digest before mass spectrometry analy-
sis; moreover, antigen specificity cannot yet be predicted de novo from the primary immuno-
globulin sequence. As a result, mass spectrometry is currently not well suited to the challenge 
of autoantibody biomarker discovery [61]; alternative technological platforms are therefore 
required to unravel the complexity of the human immunoglobulin repertoire and to detect 
and quantify novel autoantibody/autoantigen pairs in biological samples.
4.4. Serologic proteome analysis
Serologic Proteome Analysis (SERPA) is a classical immunoproteomics approach to autoanti-
gen discovery that provides a robust way of screening antibody reactivity profiles in sera from 
patients with various diseases. The method – which is essentially an adaption of western blot-
ting - involves separating proteins from a biological sample (e.g. a tissue homogenate or cell 
lysate) using 2-dimensional electrophoresis on large format gels and then immunoblotting 
with patient or control sera. Unique protein spots identified by following blotting with patient 
but not control sera are excised from the gels and identified by mass spectrometry. However, 
Figure 3. Types of ELISA assays.
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the inherently high gel-to-gel variability and relatively low resolving power of individual gels 
impacts on the accuracy of spot picking and imposes a limitation due to co-migrating proteins, 
which is especially problematic for low-abundance protein targets. Several modifications have 
been suggested to address such limitations, including multi-colour fluorescence-based 2-D 
gel immunoproteomics approaches [62], but these still do not address the fundamental issues 
of the limited resolving power of the gels, the modest limit of detection or the throughput for 
SERPA. This technology is thus less widely used for autoantigen discovery now and has been 
largely supplanted by newer technologies that are better able to overcome these limitations.
4.5. Serological analysis of recombinant cDNA expression libraries (SEREX)
SEREX is one of the oldest methods for autoantigen discovery and utilises human cDNA 
expression libraries to profile autoantibody repertoires. The methodology for SEREX initially 
involves generation of a cDNA library from a cancer tissue or tumour cell line, followed by 
cloning of that library into a suitable expression vector, clonal separation of the library and 
expression of the encoded proteins in Escherichia coli cells grown on solid media. Colonies are 
then transferred to a nitrocellulose or PVDF membrane, lysed and the expressed recombinant 
proteins blotted with sera from patients and healthy controls. Sero-reactive proteins are then 
identified by sequencing the cDNA from positive colonies [63], which makes it more sensitive 
than the SERPA method since the latter relies on direct protein identification and is therefore 
limited by absolute protein abundance. Furthermore, the clonal separation of the members 
of the cDNA expression library provides greater resolving power than the gel-based SERPA 
method. However, as with all library-based screening methods, over-sampling is required to 
ensure that all members of the library are examined in SEREX: thus, if for example the cDNA 
library contains 104 unique clones, then at least 105 colonies would need to be screened for 
complete coverage, so even with the advent of colony picking and arraying robots, SEREX 
remains a relatively low throughput method.
The first cancer testis antigen, NY-ESO-1, was identified by SEREX by analysing tumour asso-
ciated antigens (TAAs) that elicited a high titre IgG antibody in sera from patients with dif-
ferent types of cancer [64]. SEREX has also been successfully used to identify several TAAs 
that generate a humoral immune response in cancers such as those from the kidney, lung, 
breast and colon [63]. However, a fundamental limitation of SEREX is that the method lacks 
the ability to differentiate or detect post-translational modifications (PTMs) that are likely 
to play a significant role in autoimmune diseases [62] and cancers [63]. This approach also 
restricts the types of TAAs identified to those that can be expressed in a prokaryotic system 
and also effectively excludes TAAs that require folding mechanisms unique to eukaryotes to 
achieve the correct conformational epitope for recognition [63]. SEREX may also miss TAAs 
that are represented by truncated cDNAs in the library, since the encoded protein may lack 
specific epitopes or even whole domains. Furthermore, identification of TAAs is inherently 
limited to those that were expressed by the specific patient tumour or cell line from which the 
cDNA library was derived, which means that more than one cDNA library may be required to 
identify comprehensive set of TAAs for different cancers [63]. In addition, the presence of the 
crude prokaryotic cell lysate in every spot can give rise to high background binding in SEREX 
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assays. Thus, for many of these reasons, SEREX has largely been superseded now by protein 
microarray technologies that are based on purified recombinant proteins.
5. Protein microarrays
Protein microarrays are a versatile, miniaturised platform used to simultaneously character-
ise the biomolecular interactions of thousands of different proteins that are spotted in defined 
locations on a solid support; as such, protein microarrays represent a natural technological 
evolution from ELISA, SERPA and SEREX. Protein microarrays in principle allow the quan-
titative analysis of binding of a wide variety of analytes - including antibodies, proteins, 
DNA, RNA, small molecules, lipids, enzymes as well as peptides - to the arrayed proteins. 
The three types of protein microarrays that are commonly used are analytical, functional 
and reverse-phase microarrays. Analytical protein arrays, or antibody arrays, are ideal for 
quantification of different known proteins in a biological sample, monitoring protein expres-
sion levels and protein profiling in what amounts to miniaturised, highly multiplexed ELISA 
assays. Functional protein microarrays can be sub-divided into those based on recombinant 
proteins and those based on native proteins and can be used for autoantibody and immune 
response profiling, biomolecular interaction profiling and identification of enzyme substrates, 
amongst others [1]. Reverse-phase protein arrays are comprised of spots of different crude 
tissue homogenates or cell lysates and are suited for detection of known proteins in multiple 
tissues/cells based on blotting of the reverse-phase arrays with antigen-specific antibodies. In 
general, protein microarrays can be applied in diagnostic and therapeutic research, through 
new biomarker discovery for disease staging and monitoring, potential drug-target evalua-
tion and for identification of new drug targets. Of the different protein array types, functional 
protein arrays appear best suited to autoantigen discovery and autoantibody profiling and 
are discussed in more detail below.
5.1. Recombinant protein production
Different protein production systems can be employed to produce recombinant proteins in 
sufficient quantities for protein microarray fabrication. The key problem associated with 
recombinant protein production is identifying the best expression system for a particular pro-
tein. To date, there is no universally applicable protein expression system [65]. Each system 
has its advantages and disadvantages; therefore, the choice of expression system selection 
should be based on the properties of the recombinant protein as well as the scale of expres-
sion required. Although exploring multiple expression systems in parallel sounds enticing, 
factors such as protein solubility, yield, speed and cost need to be taken into consideration as 
it involves substantial resources. Choosing the right system for protein expression can be par-
ticularly important in obtaining biologically active and functional recombinant proteins [1].
Bacteria, notably E. coli, represent the most commonly used expression systems for protein 
production since they give high protein yields at a relatively low cost, require simple and 
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rapid culture conditions, and are highly scalable. In addition, many parameters can be altered 
to optimise expression levels of protein. However, inefficient disulfide bond formation, insol-
ubility, aggregation and poor folding of proteins have been reported using this method, as 
well as very minimal capability in performing post-translational modifications [65].
Expression of proteins in yeast is a common alternative to prokaryotic expression systems 
as it is a well-defined and economical eukaryotic expression system. Commonly used yeast 
strains include Saccharomyces cerevisiae and Pichia pastoris, although other yeast strains have 
also been reported. Proteins expressed using both strains fold efficiently and numerous post-
translational modifications can occur; P. pastoris typically gives better protein yields than S. 
cerevisiae [65]. However, a major disadvantage of the yeast expression systems is that they do 
not mimic protein glycosylation patterns from mammalian cells, with proteins tending to be 
hyperglycosylated due to the presence of large mannose glycans. Furthermore, lysis condi-
tions for yeast are typically harsh and induce many endogenous proteases, meaning that the 
extracted recombinant proteins are often significantly proteolysed.
Baculoviruses belong to a diverse group of large double-stranded DNA viruses that infect 
many different species of insects as their natural hosts but are highly species-specific and are 
not known to propagate in any non-invertebrate host. Baculoviral expression systems yield 
good expression levels, especially for intracellular proteins, and typically produce function-
ally active, recombinant mammalian proteins that are properly folded and oligomerised and 
which contain correct disulfide bonds, as well as mammalian-like post-translational modifica-
tions, including glycosylation, so are both structurally and functionally similar to their native 
counterparts [65].
Mammalian expression systems are preferred by some researchers as they produce more 
‘humanised’ proteins, with the most biologically-relevant post-translational modifications 
and native folding. Amongst the most widely used mammalian cells include HeLa, human 
embryonic kidney-derived (HEK293) epithelial cells, Chinese hamster ovary cells (CHOs) and 
African green monkey kidney cells (COS). However, mammalian protein expression systems 
require more demanding culture conditions compared to other systems [65] so are signifi-
cantly more challenging for high throughput expression purposes.
5.2. Surface chemistry
The microarray surface chemistry plays a critical role in determining protein microarray qual-
ity. Slide surfaces vary: aldehyde and epoxy-derivatized glass surfaces are used for random 
attachment through amines, whereas nitrocellulose, hydrogel or metal surfaces for attachment 
of affinity-purified proteins. An ideal surface chemistry should resist nonspecific adsorption, 
whilst preserving the folded structure of the arrayed proteins [1].
Common challenges associated with slide surface chemistry include high background and 
incorrect protein orientation or conformation of proteins, whereby all functional binding 
sites are not readily available for interaction. Proteins have various hydrophobic domains 
and charged patches, so tend to adsorb non-specifically to most solid surfaces resulting in the 
disruption of protein 3-D structure and eventually complete loss of activity. This indirectly 
Autoantibodies and Cytokines174
gives rise to the second issue - the loss of protein conformation upon immobilisation. In par-
ticular, when the functional domains interact excessively with a solid surface, the orientation 
of the proteins may be altered or completely lost, resulting in the subsequent disruption of the 
functional domains and loss of discontinuous epitopes [66]. Partial or complete denaturation 
of proteins on the arrayed surface is also deleterious for downstream autoantibody binding 
since it is well known that antibodies tend to bind non-specifically to exposed hydrophobic 
epitopes, giving rise to false positive signals in autoantibody profiling assays.
Proteins can be immobilised onto a microarray surface via encapsulation, surface adsorption, 
covalent attachment or affinity binding (Figure 4), which are further described below [67].
Encapsulation of a purified protein on a solid surface involves suspending the protein in a 
random orientation within a 3D gel pad (e.g. acrylamide or agarose) on an array surface; this 
approach provides a high capacity for immobilisation and thereby enhances the sensitivity 
of subsequent assays. A drawback of the technique, however, is that the size of the protein 
or other ligand applied may restrict diffusion into the gel, resulting in stronger signals at 
the periphery of the gel pad. This challenge may be surmounted when using different cross-
linkers that can improve the porosity of the gel pads [68].
Immobilisation of purified proteins via noncovalent adsorption is a straightforward, revers-
ible method that involves protein attachment onto a solid support through weak, non-specific 
interactions, including van der Waals hydrophobic interactions and electrostatic interactions. 
Commonly used surfaces here include nitrocellulose-coated and amine-terminated glass 
slides. Although this approach can provide high protein loading onto the surface, the orienta-
tion of the immobilised protein cannot be controlled, resulting in variable reaction efficiency, 
accuracy and reproducibility of the resultant arrays [69]. Furthermore, the underlying sur-
faces tend to be relatively denaturing towards the arrayed proteins [1].
Covalent attachment takes place by chemically cross-linking proteins to the surface through 
the nucleophilic residues lysine or cysteine. These residues are cross-linked to surface-bound 
ligands that are terminated with aldehyde, epoxy, or N-hydroxysuccinamide moieties. 
Irreversible immobilisation of a wide range of proteins to the carrier surfaces are feasible using 
covalent attachment, but the non-specific modification of surface residues on the arrayed pro-
tein carries the risk of altering the activity and folded structure of those proteins [70].
Affinity capture is a particularly advantageous way to immobilise proteins, since it circum-
vents many of the limitations of other approaches described above. Typical affinity capture 
methods include use of biotinylated, hexa-His-tagged, glutathione S transferase tagged or 
Halo tagged recombinant proteins [1], with orientation of the immobilised protein being con-
trolled via the tag, thereby aiding in preserving the structure and function of the arrayed 
proteins.
Numerous human protein microarray platforms are available today for autoantibody research, 
including Immunome arrays (Sengenics, Singapore), Nucleic Acid Programmable Arrays 
(BioDesign Institute, Arizona), Human Protein Atlas Protein Fragment Arrays (SciLifeLab, 
Sweden), HuProt arrays (CDI Laboratories, USA) and ProtoArrays (ThermoFischer, USA). 
These various human protein microarray platforms have differing protein content and make 
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different use of the various protein expression systems, surface chemistries and immobilisa-
tion strategies described above, all of which gives rise to differences in technical performance, 
as has been reviewed recently [1].
By way of example, proteins on the Immunome array are expressed in a baculoviral sys-
tem as in-frame fusions to a biotin carboxyl carrier protein (BCCP) folding marker, that itself 
becomes biotinylated in vivo or in vitro only when the fusion protein is correctly folded. 
Immunome’s surface chemistry is based on a hydrogel polymer that dramatically reduces 
non-specific background binding to the array surface whilst providing an aqueous-like envi-
ronment for the arrayed proteins. The hydrogel matrix is derivatised with a low density of 
streptavidin molecules that are held away from the underlying array substrate, providing 
a selective surface for binding of biotinylated proteins (Figure 5). This helps to ensure that 
each protein immobilised on the array retains its native conformation, correctly folding and 
functionality on the array surface.
Figure 4. Various methods of protein immobilisation onto a solid support; encapsulation, surface adsorption, covalent 
cross-linking and affinity attachment.
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5.3. Sensitivity and reproducibility
Quantification of autoantibody biomarkers using a protein microarray starts with the pro-
duction of recombinant proteins, printing of the proteins onto a solid support, probing them 
with serum or plasma samples and finally capturing interactions using fluorescent-labelled 
secondary antibodies. Protein microarrays have thus often been referred to as miniaturised 
version of ELISA. Miniaturisation allows a high overall sensitivity as analyte measurement is 
conducted while retaining the highest concentration per unit volume attainable for the given 
sample, with decreased reaction times due to short diffusion distances [71]. Furthermore, 
fluorescent-based signal detection in protein microarrays offers lower limits of detection (as 
low as 1 pg/mL; [72]) and greater dynamic range (up to 5 orders of magnitude; [73]) than 
colourimetric readouts in typical ELISAs. In addition to their greater sensitivity compared to 
ELISA, protein arrays are also superior in terms of multiplexing, as thousands of proteins can 
be printed onto glass slides in replicates and analysed simultaneously.
Given the capacity for multiplexing, as well as the high-throughput, low sample consump-
tion, remarkable sensitivity and reproducibility of protein arrays, this platform is rapidly 
proving now to be very well suited to the challenges of autoantibody biomarker discovery. 
However, when choosing the optimal platform for discovery research, important factors such 
as the protein expression system used and the surface chemistry of the platform should be 
considered carefully to ensure that only biologically-meaningful autoantibody biomarkers 
that have the potential to be translated into clinical use will be discovered.
5.4. Protein microarray-based autoantibody discovery
Microarrays fabricated with proteins derived from tissues or cell-line, or recombinant pro-
teins have been used in many studies to identify potential autoantibody biomarkers for can-
cer, a few examples of which follow.
Figure 5. Depiction of the slide surface chemistry of the immunome protein array. Individually-purified BCCP-tagged 
proteins are immobilised onto customised hydrogel-coated surfaces such that they retain folded structure and function 
in an aqueous environment and behave as if they are in free solution.
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Native protein microarrays: Nam et al. demonstrated the feasibility of manufacturing a native 
protein microarray using chromatographic techniques and microarray printing technology. 
Here, a crude cell lysate was resolved in 2 dimensions using liquid-based isoelectric focus-
ing followed by reverse-phase liquid chromatography, resulting in 1760 fractions which 
were then printed on a nitrocellulose surface and used to screen sera from cancer patients 
vs. healthy controls to identify fractions containing cancer-specific reactive autoantigens. 
Fractions corresponding to reactive spots were analysed using mass spectrometry to identify 
cancer-specific autoantigens, which revealed that 9/15 colon cancer patients, but neither of the 
healthy controls, produced autoantibodies against ubiquitin C-terminal hydrolase isozyme 
(UCH-L3). Autoantibody production against UCH-L3 was confirmed by Western blot in 19 of 
43 (44%) additional colon cancer patients [74].
Antibody microarrays: in order to identify prostate cancer-associated autoantibodies, well-
characterised monoclonal antibodies were arrayed onto nanoparticle slides to capture native 
antigens from prostate cancer cells, which were subsequently incubated with fluorescently-
labelled IgG from patients with prostate cancer and benign prostate hyperplasia (BPH). The 
study revealed that prostate cancer patients had higher autoantibody levels against TLN1, 
TARDBP, LEDGF, CALD1, and PARK7 when compared to patients with BPH. The study con-
cluded that PSA alone produced sensitivity- and specificity-values of 12.2 and 80%, respec-
tively, whereas the collective panel produced sensitivity- and specificity-values of 95 and 
80%, respectively [75].
Functional protein microarrays: a cancer antigen microarray, comprising 123 full length, folded, 
recombinant tumour-associated antigens expressed in insect cells was used to identify auto-
antibodies that differentiate prostate cancer patients from benign prostatic hyperplasia 
(BPH) and other disease controls. The study identified 41 potential diagnostic/therapeutic 
antigen biomarkers for prostate cancer and found that autoantibody titres against GAGE1, 
ROPN1, SPANX1 and PRKCZ were high in prostate cancer patients, whereas autoantibody 
titres against MAGEB1 and PRKCZ were higher in BPH controls. Of the 41 potential antigens 
identified, FGFR2, COL6A1 and CALM1 were identified in urine from the same patients by 
shotgun proteomics [76].
Functional protein microarrays have also been used to identify autoantibodies against auto-
antigens in a number of other infectious or autoimmune-related diseases, including malaria 
and Parkinson’s disease (PD). In malaria, Plasmodium knowlesi infection results in an autoim-
mune-like response in some individuals that has been hypothesised to play a protective role 
against malarial infection. Using the Sengenics Immunome protein array comprising 1636 
correctly folded human antigens, 24 antigens with high reactivity to serum autoantibodies 
were identified, which may serve as potential biomarkers for asymptomatic malaria, mild 
malaria, or predictive biomarkers for severe malaria [77].
PD is a chronic and progressive neurodegenerative disorder, and a positive correlation is asso-
ciated with Helicobacter pylori (H. pylori) and PD motor severity. The Sengenics Immunome pro-
tein array was used to screen H. pylori-seropositive PD patients and H. pylori-seronegative PD 
patients in a study that identified 13 significant autoantibodies, of which 8 were up-regulated 
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and 5 down-regulated in the case group. Identified autoantigens included Nuclear factor I 
subtype A (NFIA), Platelet-derived growth factor B (PDGFB) and Eukaryotic translation initia-
tion factor 4A3 (elFA3) [78].
Other protein microarray platforms, including nucleic acid programmable protein arrays 
(NAPPA), HuProt arrays, Protoarrays and Human Protein Atlas Protein Fragment Arrays, 
have also found utility in autoantibody biomarker discovery applications across a wide vari-
ety of disease areas, including a broad spectrum of cancers and autoimmune diseases, as 
well as several neurological disorders and inflammatory disorders, as recently reviewed else-
where [1].
6. Biomarker validation
Biomarkers can be used for variety of purposes including disease prediction, diagnosis 
and treatment monitoring. However, while there are thousands of papers reporting dis-
covery of potential biomarkers, very few of these have been validated and approved by 
the Food and Drug Administration (FDA) for clinical use (Table 2), despite preliminary 
reports of good sensitivity and specificity. This highlights the reality that biomarker vali-
dation is a challenging process with multiple criteria that need to be fulfilled before the 
markers can be approved use in clinical settings. There are also multiple stages where 
attrition can occur in the validation process, including poor study design, variations in 
sample collection, and the simple failure of the biomarkers in blinded validations, as dis-
cussed further below:
A key requirement for all biomarker validation is that the biomarker demonstrates a correla-
tion with specific pathophysiological processes or serves as a surrogate endpoint in a clinical 
trial. Diagnostic precision and accuracy are key technical parameters, since inaccurate or vari-
able results, as well as false positive and false negative results, could lead to misdiagnosis that 
could bring about unwanted sequelae.
Typical biomarker discovery programs are initially set up as case–control studies, with clearly 
defined and well-separated clinical groups. However, in real world settings, the diagnostic 
challenge is often not to distinguish diseased from healthy, but to differentiate amongst peo-
ple with similar clinical symptoms but different underlying disorders. As a first step towards 
validation therefore, once candidate biomarkers have been identified from an initial discovery 
study, a scientifically sound and statistically-powered validation cohort needs to be designed 
to test the diagnostic power of the biomarkers in the context of ‘diseased patients’ and ‘other 
disease’ controls. Power calculations are used to determine the sample size required to iden-
tify reproducible, precise and accurate biomarkers that qualify for clinical utilisation and this 
cohort is then typically sub-divided into a training cohort and a larger blinded validation 
cohort. Typically, the clinical sensitivity and specificity of a larger set of candidate biomarkers 
from the discovery research is first assessed in the training cohort and the best performing 
markers that survive are taken forward for further evaluation in the blinded validation cohort.
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Biomarker Cancer type Clinical use Specimen
Pro2PSA Prostate Discriminating cancer from 
benign disease
Serum
Free PSA Prostate Discriminating cancer from 
benign disease
Total PSA Prostate Prostate cancer diagnosis and 
monitoring
ROMA (HE4 + CA-125) Ovarian Prediction of malignancy
OVA1 (multiple proteins) Ovarian Prediction of malignancy
HE4 Ovarian Monitoring recurrence or 
progression of disease
Fibrin/fibrinogen degradation 
product (DR-70)
Colorectal Monitoring progression of 
disease
AFP-L3% Hepatocellular Risk assessment for 
development of disease
CA27.29 Breast Monitoring disease response to 
therapy
CA15–3 Breast Monitoring disease response to 
therapy
Serum, plasma
CA19–9 Pancreatic Monitoring disease status
CA-125 Ovarian Monitoring disease 
progression, response to 
therapy
Thyroglobulin Thyroid Aid in monitoring
Alpha-fetoprotein (AFP) Testicular Management of cancer
Carcinoembryonic antigen Not specified Aid in management and 
prognosis
p63 protein Prostate Aid in differential diagnosis FFPE tissue
c-Kit Gastrointestinal stromal 
tumours
Detection of tumours, aid in 
selection of patients
Oestrogen receptor (ER) Breast Prognosis, response to therapy
Progesterone receptor (PR) Breast Prognosis, response to therapy
Her-2/neu Breast Assessment for therapy
Circulating tumour cells (EpCAM, 
CD45, cytokeratins 8, 18+, 19+)
Breast Prediction of cancer 
progression and survival
Whole blood
Nuclear Mitotic Apparatus protein 
(NuMA, NMP22)
Bladder Diagnosis and monitoring of 
disease (professional and home 
use)
Urine
Alpha-fetoprotein (AFP) Testicular Management of cancer Amniotic fluid
Human haemoglobin (faecal occult 
blood)
Colorectal Detection of faecal occult blood 
(home use)
Faeces
Table 2. List of FDA-approved tumour markers commonly used in clinical practice which mainly consist of serum and 
plasma biomarkers.
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Statistically-powered validation cohorts often run into hundreds of patients, so obtaining 
quality serum or plasma samples in sufficient quantities from a disease cohort, as well as 
from matched healthy and other disease controls, can therefore sometimes be a challenge. 
Furthermore, biomarker validation is a complex and lengthy process, meaning that the vali-
dation assay methods themselves need to be rapid, robust, reproducible, inexpensive and 
easy to setup and run, potentially in different laboratories.
Even after considering the aforementioned factors, it often turns out that the candidate bio-
marker is simply not robust, sensitive or specific enough to penetrate into a clinical setting. 
Ideal candidates for multiplexed panels would be markers whose qualitative and/or quan-
titative expression is unique to the disease. However, particularly in the case of cancers, 
identifying truly disease specific markers has proved problematic; for example, MAGE-A3 
was originally thought to be ‘tumour specific’ marker but was later found to be detectable 
in healthy tissues as well [71]. It is therefore not surprising that biomarkers with early diag-
nostic potential initially obtained in studies conducted in laboratory settings can often not be 
confirmed in later clinical validation and screening settings, resulting in high attrition rates 
during biomarker validation.
7. Conclusion
Autoantibodies have gained considerable attention in the medical diagnostic field as candi-
date diagnostic and prognostic biomarkers in many different disease areas, since they are 
in theory detectable many years before clinical symptoms appear. This particular property 
of autoantibodies makes them attractive tools for early diagnosis of disease. However, iden-
tification and validation of autoantibody biomarkers has historically been constrained by 
the available technological approaches and the high attrition rates during studies on larger 
cohorts.
To increase the success rate in biomarker discovery and validation, the correct technique 
as well as the right number of samples and analytes to be used for each phase should be 
carefully planned and designed as depicted in Figure 6. The current gold standard for 
biomarker validation remains ELISA, which is regularly utilised for confirmatory stud-
ies as it allows a relatively high-throughput of samples and is a versatile and robust 
tool. Thus, protein microarray analysis is often compared against the quantitative data of 
ELISA assays [79]. However, ELISAs routinely permit only single antigen detection per 
well and often require relatively large volumes of samples compared to other more minia-
turised, high-throughput methods. This leaves substantial scope for protein microarrays 
to be used in both the discovery and validation of panels of autoantibody biomarkers, 
since they represent a sensitive, highly reproducible, multiplexed and high throughput 
experimental platform for autoantibody quantitation; this will undoubtedly be aided by 
the underlying protein microarray platforms themselves gaining regulatory approval for 
use as clinical diagnostics.
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